A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome

Therapeutic Advances in Endocrinology and Metabolism
Mohammed AbdallaThozhukat Sathyapalan

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Metabolic sequelae associated with PCOS range from insulin resistance to type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Insulin resistance plays a significant role in the pathophysiology of PCOS and it is a reliable marker for cardiometabolic risk. Although insulin sensitising agents such as metformin have been traditionally used for managing metabolic aspects of PCOS, their efficacy is low in terms of weight reduction and cardiovascular risk reduction compared with newer agents such as incretin mimetics and SGLT2 inhibitors. With current pharmaceutical advances, potential therapeutic options have increased, giving patients and clinicians more choices. Incretin mimetics are a promising therapy with a unique metabolic target that could be used widely in the management of PCOS. Likewise, bariatric procedures have become less invasive and result in effective weight loss and the reversal of metabolic morbidities in some patients. Therefore, surgical treatment targeting weight loss becomes increasingly common in the management of obese women with PCOS. Newer emerging therapies, including twincretins, triple GLP-1 agonists...Continue Reading

References

Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R E OstlundW R Sherman
Apr 4, 1998·Obesity Research·B J RollsJ S Ulbrecht
Dec 17, 1998·American Journal of Obstetrics and Gynecology·D Guzick
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Feb 12, 2002·The Journal of Clinical Endocrinology and Metabolism·Richard FlemingNaveed Sattar
Jul 20, 2002·Pharmacotherapy·Jennifer R McDuffieJack A Yanovski
Sep 17, 2004·The EMBO Journal·Yoontae LeeV Narry Kim
Oct 6, 2004·Expert Opinion on Investigational Drugs·Bulent O Yildiz
Nov 13, 2004·The Journal of Clinical Endocrinology and Metabolism·V JayagopalS L Atkin
Dec 30, 2004·The Journal of Clinical Endocrinology and Metabolism·Teimuraz ApridonidzeJohn E Nestler
May 12, 2005·The Journal of Clinical Endocrinology and Metabolism·Lyndal R HarborneRichard Fleming
Sep 29, 2005·The Journal of Clinical Endocrinology and Metabolism·Héctor F Escobar-MorrealeJosé L San Millán
Nov 18, 2005·The New England Journal of Medicine·Thomas A WaddenAlbert J Stunkard
Dec 20, 2005·Nutrition & Metabolism·John C MavropoulosEric C Westman
Feb 28, 2006·Fertility and Sterility·Crystal C DouglasRicardo Azziz
Aug 24, 2006·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·George M EidPhilip R Schauer
Feb 17, 2007·Clinical Obstetrics and Gynecology·Paulina A EssahJohn E Nestler
May 24, 2007·The Journal of Clinical Endocrinology and Metabolism·Stefano PalombaFrancesco Orio
Dec 7, 2007·The Journal of Clinical Endocrinology and Metabolism·Kelsey E S SalleyJohn E Nestler
Dec 12, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·D FlorakisD Panidis
Jan 9, 2008·Seminars in Reproductive Medicine·Pinar H Kodaman, Antoni J Duleba
Mar 13, 2008·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Alessandro D GenazzaniValerio M Jasonni
Mar 29, 2008·Metabolic Syndrome and Related Disorders·P G SundararamanMeena Umachander
May 31, 2008·European Journal of Endocrinology·Jana VrbikovaGiovanni Pacini
Oct 23, 2008·The Journal of Clinical Endocrinology and Metabolism·Thozhukat SathyapalanStephen L Atkin
Oct 29, 2008·BMC Endocrine Disorders·Debora Williams-HermanJohn M Amatruda
Jan 24, 2009·Nature Reviews. Molecular Cell Biology·V Narry KimMikiko C Siomi

❮ Previous
Next ❯

Citations

Oct 2, 2020·International Journal of Molecular Sciences·Vittorio UnferMariano Bizzarri
Dec 19, 2020·International Journal of Molecular Sciences·Andrea CignarellaCarla Scaroni
Nov 5, 2020·International Journal of Molecular Sciences·Kok-Min SeowPeng-Hui Wang
Feb 9, 2021·Therapeutic Advances in Endocrinology and Metabolism·Mohammed Altigani AbdallaThozhukat Sathyapalan
Nov 7, 2020·International Journal of Molecular Sciences·Régine P M Steegers-TheunissenKevin D Sinclair
Jul 31, 2021·World Journal of Diabetes·Jelena Marinkovic-RadosevicAnna Mrzljak

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
gastric bypass
contraception

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.